VIVES Partners is a venture capital fund initiated by UCLouvain in 2004, dedicated to supporting early-stage science-based and technology-driven start-ups with positive societal impact, primarily in life sciences, AgTech, and hard engineering.
They made 1 investments in the last 12 months. Their most common stage is series-a (43% of deals). Average disclosed round size is $90.0M (across 4 rounds with reported amounts).
Portfolio
5
Fund Size
$80.5M
Top Stage
Series A
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 E-peas | Seed | $22M | Jul 2026 |
| NNUCLIDIUM AG | Unknown | — | May 2026 |
 Nuclidium | Series B | — | Jan 2025 |
| NNUCLIDIUM AG | Series B | — | Jan 2025 |
| E-peas | Series A | $8M | Jan 2020 |
| BBionyra | Series A | $165M | — |
 Bionyra Pharma | Series A | $165M | — |
Top Co-Investors
Angelini Ventures3 shared
Wellington Management3 shared
Bayern Kapital3 shared
DeepTech & Climate Fonds (DTCF)3 shared
Neva SGR3 shared
NRW.BANK3 shared
Eurazeo2 shared
HighLight Capital2 shared
Airbus Ventures2 shared
Noshaq2 shared
KBC Focus Fund2 shared
LeanSquare2 shared
Sanofi Ventures2 shared
Apollo Health Ventures2 shared
Jeito Capital2 shared
Sixty Degree Capital2 shared
Arkin Bio Ventures2 shared
Sofinnova Partners2 shared
Kurma Partners1 shared
SFPIM1 shared
Last updated: 8 September 2026